Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole IM Depot Extension Study in Schizophrenia
NCT01683058Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jan 2013
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of aripiprazole in schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Jan 2013; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01683058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01683058.